What is InnoGenomics Technologies?
InnoGenomics Technologies, LLC operates at the intersection of molecular biology and forensic science, providing critical infrastructure for human identification. The company is best known for its proprietary SpermX Differential Extraction System, a specialized tool designed to isolate male DNA from complex forensic samples. Beyond extraction, their portfolio includes the InnoTyper 21 typing system and the InnoQuant HY assay, both of which are engineered to meet the rigorous demands of forensic laboratories. By focusing on high-sensitivity DNA profiling, InnoGenomics addresses a vital market need for accuracy in sexual assault processing and criminal investigations, effectively positioning itself as a key technology provider for law enforcement and forensic service providers globally.
How much funding has InnoGenomics Technologies raised?
InnoGenomics Technologies has raised a total of $84K across 1 funding round:
Debt
$84K
Debt (2021): $84K with participation from PPP
Key Investors in InnoGenomics Technologies
PPP
Public-Private Partnership
What's next for InnoGenomics Technologies?
With the recent influx of capital, InnoGenomics Technologies is expected to prioritize the scaling of its laboratory services and the further commercialization of its DNA profiling assays. The company's current lifecycle stage, characterized by significant Series B/C growth, suggests a strategic pivot toward expanding its market share within the forensic diagnostics industry. Future initiatives will likely focus on enhancing the throughput of their existing product line and potentially diversifying their analytical capabilities to address emerging challenges in forensic genomics. As the demand for high-fidelity DNA evidence continues to rise, InnoGenomics is strategically aligned to capitalize on the modernization of forensic laboratory workflows, ensuring that their technological solutions remain at the forefront of the industry.
See full InnoGenomics Technologies company page
